UPCOMING – BioStock Life Science Summit, Stockholm, October 23 2019, Monica Wallter, CEOPress releases
LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ) Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect LIDDS Delårsrapport april – juni 2019 LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019Events
Presentations
Company Analysis
Photo Library
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2019-09-24 LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
- 2019-09-24 Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect
- 2019-08-29 LIDDS Delårsrapport april – juni 2019
- 2019-08-28 LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
